Retatrutide targets GLP-1, GIP, and glucagon receptors simultaneously
Depending on the situation, your healthcare provider may decide to adjust your medication or try other approaches to manage the vertigo
Increased Cellular Repair and Regeneration
[1] Serious gastrointestinal events were not prominently reported in the available phase 2 data, though the limited duration and sample size of phase 2 studies mean that longer-term phase 3 data will provide a more complete safety picture
[1] Orforglipron is also chemically different from previous oral GLP-1s
Platelet activation triggers further leukocyte activation and promote RBC adhesion to an exposed endothelium ( ex vivo studies, and was well tolerated by patients, but on a 24-month follow up, patients on the treatment arm failed to show reduction in the frequency of VOC (Kanter et al., 2019) (ClinicalTrials.gov identifier: NCT02482298)